HoFH

Beyond the LDL Receptor: Why ANGPTL3 Inhibition Is the New Gold Standard for Homozygous Familial Hypercholesterolemia

Clinical trials and meta-analyses demonstrate that ANGPTL3 inhibitors, including SHR-1918 and zodasiran, provide superior LDL-C reduction compared to PCSK9 inhibitors in HoFH, particularly in patients with null-receptor genotypes where trad